KR20230117120A - 인터류킨-18 변이체 및 사용 방법 - Google Patents

인터류킨-18 변이체 및 사용 방법 Download PDF

Info

Publication number
KR20230117120A
KR20230117120A KR1020237018440A KR20237018440A KR20230117120A KR 20230117120 A KR20230117120 A KR 20230117120A KR 1020237018440 A KR1020237018440 A KR 1020237018440A KR 20237018440 A KR20237018440 A KR 20237018440A KR 20230117120 A KR20230117120 A KR 20230117120A
Authority
KR
South Korea
Prior art keywords
polypeptide
seq
variant
cell
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018440A
Other languages
English (en)
Korean (ko)
Inventor
애런 링
톰 분
Original Assignee
심카 아이엘-18, 인크.
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심카 아이엘-18, 인크., 예일 유니버시티 filed Critical 심카 아이엘-18, 인크.
Publication of KR20230117120A publication Critical patent/KR20230117120A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237018440A 2020-11-02 2021-11-02 인터류킨-18 변이체 및 사용 방법 Pending KR20230117120A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108794P 2020-11-02 2020-11-02
US63/108,794 2020-11-02
PCT/US2021/057741 WO2022094473A1 (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use

Publications (1)

Publication Number Publication Date
KR20230117120A true KR20230117120A (ko) 2023-08-07

Family

ID=81384408

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018440A Pending KR20230117120A (ko) 2020-11-02 2021-11-02 인터류킨-18 변이체 및 사용 방법

Country Status (14)

Country Link
US (3) US11850276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4236990A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550545A (cg-RX-API-DMAC7.html)
KR (1) KR20230117120A (cg-RX-API-DMAC7.html)
CN (1) CN116723851A (cg-RX-API-DMAC7.html)
AR (1) AR123978A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021371040C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197145A1 (cg-RX-API-DMAC7.html)
GB (1) GB2617483B (cg-RX-API-DMAC7.html)
IL (1) IL302517A (cg-RX-API-DMAC7.html)
MX (1) MX2023005068A (cg-RX-API-DMAC7.html)
NZ (1) NZ800435A (cg-RX-API-DMAC7.html)
TW (1) TW202233657A (cg-RX-API-DMAC7.html)
WO (1) WO2022094473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
EP4584287A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4655310A2 (en) * 2023-01-24 2025-12-03 Simcha Il-18, Inc. Methods and compositions for combination therapy
WO2024259270A2 (en) * 2023-06-16 2024-12-19 Simcha IL-18, Inc. Administration of engineered interleukin-18 therapeutics
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
CN120189493A (zh) * 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026050249A1 (en) * 2024-08-26 2026-03-05 Simcha IL-18, Inc. Methods of treating cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP1669454A3 (en) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP2007143555A (ja) * 1996-11-29 2007-06-14 Hayashibara Biochem Lab Inc ポリペプチド
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU2001275166B2 (en) 2000-06-02 2005-07-28 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−18変異体、その産生および使用
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
WO2011080733A1 (en) * 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7795181B2 (ja) * 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
JP2020143000A (ja) * 2019-03-04 2020-09-10 大陽日酸株式会社 融合タンパク質及びその製造方法、目的タンパク質の製造方法
US12029778B2 (en) * 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN116368148A (zh) * 2020-08-19 2023-06-30 明峰治疗股份公司 修饰的il-18多肽及其用途

Also Published As

Publication number Publication date
US11850276B2 (en) 2023-12-26
AR123978A1 (es) 2023-02-01
MX2023005068A (es) 2023-07-14
GB2617483B (en) 2025-03-12
EP4236990A1 (en) 2023-09-06
GB202308183D0 (en) 2023-07-19
WO2022094473A1 (en) 2022-05-05
JP2023550545A (ja) 2023-12-01
US12582701B2 (en) 2026-03-24
NZ800435A (en) 2025-12-19
US20230277625A1 (en) 2023-09-07
US20240066100A1 (en) 2024-02-29
TW202233657A (zh) 2022-09-01
AU2021371040C1 (en) 2025-05-29
AU2025203386A1 (en) 2025-06-05
US12564621B2 (en) 2026-03-03
AU2021371040B2 (en) 2025-02-13
US20240075104A1 (en) 2024-03-07
EP4236990A4 (en) 2025-03-19
AU2021371040A1 (en) 2023-06-22
IL302517A (en) 2023-07-01
CA3197145A1 (en) 2022-05-05
GB2617483A (en) 2023-10-11
CN116723851A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
US12582701B2 (en) Interleukin-18 variants and methods of use
US12403180B2 (en) Interleukin-18 variants and methods of use
US20240374679A1 (en) Interleukin-18 mimics and methods of use
WO2018132516A1 (en) Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
CA3229251A1 (en) Interleukin-12 variants and methods of use
HK40100300A (en) Interleukin-18 variants and methods of use
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902